Skip to main content
PALTC24 - AMDA Annual Conference Main banner
Purchase conference recordings
Purchase 2024 conference recordings
Back
Evaluation

Clinical Medicine

(SA23) RSV Vaccines: Are We Ready for Prime Time?

Saturday, March 9, 2024
4:30 PM – 5:30 PM CT
Room: 221
CMD Clinical Credit Recording
CME: (1) MOC: (1) CMD Clinical: (1) NP Pharmacology Hours (1)

    Session Chair/Speaker(s)

  • David A. Nace, MD, MPH (he/him/his)

    Chief, Division of Geiatric Medicine and Chief of Medical Affairs
    University of Pittsburgh & UPMC Senior Communities
    WEXFORD, PA

    Disclosure(s): No financial relationships to disclose.

    • Speaker(s)

  • Ghinwa Dumyati, MD

    Director Communicable Diseases Surveillance and Prevention Program
    University of Rochester Medical Center
    Rochester, NY

    Disclosure(s): No financial relationships to disclose.

  • Ann R. Falsey, MD

    Professor, Infectious Diseases
    University of Rochester Medical Center
    Rochester, NY

    Disclosure(s): No relevant financial relationships.

  • ES

    Elizabeth Sobczyk, MSW, MPH

    Project Director, CDC Cooperative Agreement and Grants
    AMDA – The Society for Post-Acute and Long-Term Care Medicine
    Columbia, MD

    Disclosure(s): No relevant financial relationships.

Disclosure(s):
David A. Nace, MD, MPH: No financial relationships to disclose.
Ghinwa Dumyati, MD: No financial relationships to disclose.
Ann R. Falsey, MD: No relevant financial relationships.
Elizabeth Sobczyk, MSW, MPH: No relevant financial relationships.
With the approval of new RSV vaccines, facilities and providers now have an opportunity to mitigate the serious impact of RSV in post-acute & long-term care settings (PALTC). These groundbreaking vaccines are recommended by the ACIP for use in older adults using shared decision-making. Facilities should now incorporate RSV vaccines into their vaccine programs. Clinicians must understand the impact of RSV in PALTC as well as the potential risks/benefits of these vaccines to engage in effective shared decision-making.

Through brief didactic presentations and a pro/con panel discussion using a question and answer format, this session will describe the serious impact of RSV in PALTC, review the evidence base for current RSV vaccines, outline unknown areas, and explore how to prioritize the vaccines into a facility’s vaccine program. Experience from the AMDA/CDC Moving Needles initiative provides practical implementation pearls.

Learning Objectives:

At the completion of this session, learners will be able to:
  • Describe the impact of RSV among older adults
  • Discuss data from clinical trials of two currently approved FDA approved RSV vaccines
  • Discuss uncertainties surrounding use of the two RSV vaccines
  • Identify practical actions facilities can implement to include RSV vaccines in their vaccination programs